Showing results (1-10 of 28) with videos related to
Sort By:
Pageof 3
Journal of Cardiovascular Pharmacology|September 15, 1998
Neurohormonal markers of clinical outcome in cardiovascular disease: is endothelin the best one?J C MongeThe Journal of Biological Chemistry|June 23, 1995
Differentiation of embryonal carcinoma cells to a neural or cardiomyocyte lineage is associated with selective expression of endothelin receptorsJ C Monge, D J Stewart, P CernacekArteriosclerosis and Thrombosis : a Journal of Vascular Biology|March 1, 1992
Pathogenesis of carbohydrate-induced hypertriglyceridemia using HepG2 cells as a model systemK Cianflone, S Dahan, J C Monge, et al.Thrombosis Research|May 1, 1989
Heparin and concanavalin A interaction as a model for studying the mechanism of the anticoagulant activityJ C Monge, E F Recondo, M E Fernández de RecondoCellular and Molecular Biology (Noisy-Le-Grand, France)|June 1, 1995
Interaction of concanavalin A with a fraction of dermatan sulfate containing a very high anticoagulant activityM E Fernández de Recondo, J C Monge, E F RecondoThe American Journal of Physiology|November 1, 1995
Complement C5b-9 activates cytosolic phospholipase A2 in glomerular epithelial cellsA V Cybulsky, J C Monge, J Papillon, et al.Trends in Pharmacological Sciences|March 24, 1998
Endothelin: new discoveries and rapid progress in the clinicD J Webb, J C Monge, T J Rabelink, et al.Journal of Cardiovascular Pharmacology|May 22, 1998
Expression of endothelial factors after arterial injury in the ratP Picard, P J Smith, J C Monge, et al.Journal of Cardiovascular Pharmacology|May 22, 1998
Regulation of endothelin-B receptor mRNA expression in human endothelial cells by cytokines and growth factorsP J Smith, K Teichert-Kuliszewska, J C Monge, et al.FEBS Letters|January 30, 1989
Effect of low density lipoproteins, high density lipoproteins, and cholesterol on apolipoprotein A-I mRNA in Hep G2 cellsJ C Monge, J M Hoeg, S W Law, et al.Pageof 3